Polpharma Biologics’ Vedolizumab Biosimilar PB016 Accepted for FDA and EMA Review, Advancing Access to Biologic Therapy for Inflammatory Bowel Disease
Polpharma Biologics International AG has announced that its proposed vedolizumab biosimilar, PB016, has reached an important regulatory milestone after both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) accepted the company’s marketing applications for review. The FDA has accepted the Biologics License Application (BLA), while the EMA has accepted the Marketing Authorisation Application (MAA) for PB016, a proposed biosimilar to Takeda’s reference biologic Entyvio® (vedolizumab) administered as an intravenous (IV) lyophilized formulation.
The regulatory acceptances represent a significant step toward making PB016 available to patients suffering from chronic inflammatory bowel diseases, including moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD). If approved, PB016 will provide healthcare professionals with another high-quality biosimilar treatment option that may help improve patient access to biologic therapy while reducing treatment costs across global healthcare systems.
Important Milestone for Polpharma Biologics
Acceptance of both regulatory submissions reflects the successful progression of Polpharma Biologics’ comprehensive biosimilar development program and highlights the company’s growing expertise in developing and manufacturing complex biologic medicines.
The simultaneous review by two of the world’s leading regulatory agencies demonstrates that the submitted applications meet the required standards for scientific evaluation and may now proceed through the formal regulatory review process.
For Polpharma Biologics, the achievement represents years of investment in biologics research, advanced manufacturing capabilities, analytical characterization, clinical development, and quality systems aimed at producing highly comparable biosimilar medicines.
The company views the milestone as further validation of its integrated development platform, which supports every stage of biologic production—from cell line development and process optimization to commercial manufacturing.
Commitment to Expanding Access to Biosimilars
Biologic medicines have transformed the treatment of numerous autoimmune and inflammatory diseases over the past two decades. However, their high cost often limits patient access and places substantial financial pressure on healthcare systems.
Biosimilars are developed to provide highly similar alternatives to approved biologic therapies without clinically meaningful differences in safety, efficacy, or quality. Their introduction has helped increase competition, reduce treatment costs, and improve access to advanced therapies worldwide.
Polpharma Biologics has made biosimilar development a central component of its long-term strategy, focusing on delivering affordable treatment options for patients with chronic diseases while maintaining rigorous scientific and manufacturing standards.
CEO Highlights Scientific Achievement
Commenting on the regulatory milestone, Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG, described the FDA and EMA acceptances as a major accomplishment for the organization.
He noted that the regulatory progress validates the company’s extensive scientific expertise in biosimilar development and manufacturing.
According to Selz, PB016 represents the culmination of years of coordinated work across Polpharma Biologics’ fully integrated development platform, covering every stage from cell line engineering through analytical characterization, manufacturing process development, and comprehensive clinical evaluation.
He also emphasized the importance of the company’s commercial partnership with Fresenius Kabi, stating that its global commercialization infrastructure will help ensure broad patient access to affordable biologic therapies once regulatory approvals are obtained.
About PB016
PB016 is a proposed biosimilar to vedolizumab, an integrin receptor antagonist that selectively targets inflammation within the gastrointestinal tract.
Vedolizumab works by blocking the interaction between specific integrins expressed on inflammatory immune cells and their receptors within the intestinal blood vessels. This mechanism limits the migration of inflammatory white blood cells into intestinal tissues, thereby reducing chronic inflammation associated with inflammatory bowel disease.
Unlike broader immunosuppressive therapies, vedolizumab primarily acts within the gastrointestinal tract, offering a targeted treatment approach for patients living with ulcerative colitis and Crohn’s disease.
PB016 has been developed as an intravenous lyophilized formulation that mirrors the reference medicine’s approved presentation.
Polpharma Biologics will remain responsible for manufacturing the biosimilar using its own production facilities following any future regulatory approvals.
Global Commercialization Partnership
Under an existing strategic agreement, Fresenius Kabi, an operating company of Fresenius, holds the exclusive global commercialization rights for PB016 outside the Middle East and North Africa.
The partnership combines Polpharma Biologics’ expertise in biosimilar development and manufacturing with Fresenius Kabi’s established global commercial network.
If approved, Fresenius Kabi will oversee commercialization activities across major international markets, helping accelerate product availability to healthcare providers and patients.
The collaboration is intended to support efficient market access while expanding the global availability of biosimilar treatments for inflammatory bowel disease.
Comprehensive Biosimilar Development Program
Regulatory approval of a biosimilar requires extensive evidence demonstrating that the proposed product is highly similar to the reference biologic across multiple scientific parameters.
Polpharma Biologics designed the PB016 development program to satisfy regulatory expectations established by both the FDA and EMA.
The program included:
- Extensive analytical characterization comparing structural and functional properties with the reference product
- Non-clinical evaluations
- Pharmacokinetic and safety assessments
- Comparative clinical studies evaluating efficacy, safety, and immunogenicity
These studies were conducted according to internationally recognized biosimilar development guidelines.
Clinical Evaluation
PB016 has undergone both Phase 1 and Phase 3 clinical evaluation.
The Phase 1 clinical trial assessed pharmacokinetics, safety, tolerability, and similarity in healthy volunteers.
The pivotal Phase 3 study enrolled patients with moderately to severely active ulcerative colitis, comparing PB016 with the reference vedolizumab product to evaluate therapeutic equivalence.
The clinical program was designed to generate robust evidence supporting biosimilarity across efficacy, safety, and immunogenicity endpoints.
Completion of these studies formed a critical component of the regulatory submissions accepted by both agencies.
Growing Burden of Inflammatory Bowel Disease
The need for additional biologic treatment options continues to grow as inflammatory bowel disease becomes increasingly prevalent worldwide.
Inflammatory bowel disease primarily includes two chronic disorders:
- Ulcerative colitis
- Crohn’s disease
Both conditions involve persistent inflammation of the gastrointestinal tract, leading to symptoms such as abdominal pain, diarrhea, rectal bleeding, fatigue, weight loss, and impaired quality of life.
Although the exact causes remain incompletely understood, IBD is believed to result from complex interactions among genetic susceptibility, immune dysfunction, environmental factors, and alterations in the intestinal microbiome.
The diseases typically follow a lifelong course characterized by periods of remission and relapse, often requiring long-term medical management.
Current estimates indicate that inflammatory bowel disease affects approximately 2.4 million people in the United States and between 2.5 and 3 million individuals across Europe, with incidence continuing to rise globally.
The growing prevalence places increasing demands on healthcare systems and highlights the need for accessible biologic therapies capable of controlling disease activity and preventing long-term complications.
Potential Impact of Biosimilars
Biologic therapies have significantly improved outcomes for many patients with moderate-to-severe inflammatory bowel disease by reducing inflammation, maintaining remission, and decreasing the need for surgery and hospitalization.
However, treatment costs remain a major barrier for many patients and healthcare providers.
The availability of biosimilars has the potential to increase treatment accessibility by introducing competition into the biologics market.
Lower-cost alternatives may enable broader use of advanced therapies earlier in the disease course while supporting healthcare sustainability.
If PB016 receives regulatory approval in the United States, Europe, and other global markets, it could become an important addition to the growing biosimilar landscape for inflammatory bowel disease treatment.
With both the FDA and EMA now formally reviewing the respective applications, Polpharma Biologics has entered the next phase of the regulatory process for PB016. Regulatory authorities will conduct detailed evaluations of the product’s quality, manufacturing processes, analytical comparability, clinical data, and overall benefit-risk profile before making approval decisions.
The milestone reinforces Polpharma Biologics’ position as an emerging global developer of biosimilars and reflects its continued commitment to expanding patient access to affordable biologic medicines. Through its partnership with Fresenius Kabi and its integrated development and manufacturing capabilities, the company aims to bring high-quality biosimilar therapies to patients living with chronic inflammatory diseases, supporting broader access to effective treatment options for ulcerative colitis, Crohn’s disease, and other conditions requiring advanced biologic care.
About Vedolizumab
Vedolizumab (PB016) is a monoclonal antibody that selectively targets the α4β7 integrin, reducing gastrointestinal inflammation by inhibiting the migration of lymphocytes into the gut.1
It is used in the treatment of moderately to severely active ulcerative colitis and Crohn’s disease, chronic inflammatory diseases that can significantly impact patients’ quality of life. Vedolizumab is administered by intravenous infusion.
About Polpharma Biologics International AG
Polpharma Biologics International AG orchestrates the development and commercialization of high-quality biosimilar solutions across key therapeutic areas, including immunology and inflammation, ophthalmology, and hematology. Through close collaboration with trusted CDMOs and commercial partners, Polpharma Biologics delivers end-to-end biosimilar programs designed to ensure efficient progression from concept to launch.
Polpharma Biologics International AG provides integrated program leadership and orchestration across the full biosimilar lifecycle, drawing on deep expertise in program leadership, regulatory strategy, CMC integration, device development, clinical oversight, and quality assurance. With a robust and expanding pipeline spanning multiple programs at various stages of development, the company is committed to accelerating access to high-quality biopharmaceutical therapies worldwide.